Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Genomic Surveillance and Antigenic Characterization of Respiratory Syncytial Virus (RSV) in Spain During the 2023-2024 Season of Nirsevimab Administration.

  • Iglesias-Caballero, Maria
  • Mas-Lloret, Vicente
  • Campoy, Albert
  • Calvo, Cristina
  • García, María Luz
  • Alcolea, Sonia
  • Moreno-Parrado, Laura
  • Reina, Jordi
  • Navascués, Ana
  • Antón, Andrés
  • Davina-Nunez, Carlos
  • Perez-Castro, Sonia
  • Costa, José
  • Fernández-González, Ana
  • Lepe, José Antonio
  • Gaona, Cristina
  • Pérez, Zulema
  • García-Martínez de Artola, Diego
  • Vázquez-Morón, Sonia
  • Camarero-Serrano, Sara
  • Cano, Olga
  • Pozo Sanchez, Francisco
  • Casas Flecha, Inmaculada
Respiratory Syncytial Virus (RSV) is a leading cause of respiratory infections in infants and older adults. In Spain, surveillance is supported by the SiVIRA system and the RELECOV genomic sequencing network. The 2023-2024 season marked the first nationwide administration of nirsevimab, a monoclonal antibody for preventing severe RSV in infants. This study analyzes the genomic evolution of RSV during this period, focusing on potential escape mutations in the F protein. RSV-A showed high genetic diversity with eleven circulating lineages, while RSV-B was dominated by lineage B.D.E.1. Phylogenetic analysis revealed three distinct B.D.4.1.1 groups, one sharing mutations with B.D.E.1 in the nirsevimab binding site. Despite these changes, neutralization assays confirmed that nirsevimab and other monoclonal antibodies remained effective. No significant antigenic drift compromising immunoprophylaxis was observed. These findings support the continued efficacy of nirsevimab and highlight the importance of genomic surveillance for tracking RSV evolution and informing future immunization strategies.
Repisalud
Publication Artículo científico (JournalArticle)

Second-season Impact of Nirsevimab: Clinical Outcomes of RSV Disease in Patients Immunized During Their First Season.

  • González-Bertolín, Isabel
  • Alcolea, Sonia
  • Alonso, Patricia
  • Arroyas, María
  • Fernández Castiella, Isabel
  • Echavarren, Iciar
  • Iglesias-Caballero, Maria
  • Casas Flecha, Inmaculada
  • García-García, María Luz
  • Calvo, Cristina
Nirsevimab provides passive immunization against respiratory syncytial virus, yet concerns exist regarding its long-term impact. This study analyzed respiratory syncytial virus-associated lower respiratory tract infection severity in hospitalized children immunized with nirsevimab more than 6 months prior. No significant differences were found compared with nonimmunized children. Findings suggest no increased risk in the following season, supporting nirsevimab's safety as a preventive strategy.
Repisalud
Publication Artículo científico (JournalArticle)

Gut and respiratory tract microbiota in children younger than 12 months hospitalized for bronchiolitis compared with healthy children: can we predict the severity and medium-term respiratory outcome?

  • Cabrera-Rubio, Raul
  • Calvo, Cristina
  • Alcolea, Sonia
  • Bergia, María
  • Atucha, Jorge
  • Pozo Sanchez, Francisco
  • Casas Flecha, Inmaculada
  • Arroyas, María
  • Collado, Maria Carmen
  • García-García, María Luz
Growing evidence indicates that gut and respiratory microbiota have a potential key effect on bronchiolitis, mainly caused by respiratory syncytial virus (RSV). This was a prospective study of 96 infants comparing infants with bronchiolitis (n = 57, both RSV and non-RSV associated) to a control group (n = 39). Gut (feces) and respiratory [nasopharyngeal aspirate (NPA)] microbial profiles were analyzed by 16S rRNA amplicon sequencing, and respiratory viruses were identified by PCR. Clinical data of the acute episode and follow-up during the first year after infection were recorded. Pairwise comparisons showed significant differences in the gut (R2 = 0.0639, P = 0.006) and NPA (R2 = 0.0803, P = 0.006) microbiota between cases and controls. A significantly lower gut microbial richness and an increase in the NPA microbial diversity (mainly due to an increase in Haemophilus, Streptococcus, and Neisseria) were observed in the infants with bronchiolitis, in those with the most severe symptoms, and in those who subsequently developed recurrent wheezing episodes after discharge. In NPA, the higher microbial richness differed significantly between the control group and the non-RSV bronchiolitis group (P = 0.01) and between the control group and the RSV bronchiolitis group (P = 0.001). In the gut, the richness differed significantly between the control group and the non-RSV group (P = 0.01) and between the control group and the RSV bronchiolitis group (P = 0.001), with higher diversity in the RSV group. A distinct respiratory and intestinal microbial pattern was observed in infants with bronchiolitis compared with controls. The presence of RSV was a main factor for dysbiosis. Lower gut microbial richness and increased respiratory microbial diversity were associated with respiratory morbidity during follow-up. Importance: Both the intestinal and respiratory microbiota of children with bronchiolitis, especially those with respiratory syncytial virus infection, are altered and differ from that of healthy children. The microbiota pattern in the acute episode could identify those children who will later have other respiratory episodes in the first year of life. Preventive measures could be adopted for this group of infants.
Repisalud
Publication Artículo científico (JournalArticle)

RGB-Marking to Identify Patterns of Selection and Neutral Evolution in Human Osteosarcoma Models

  • Gambera, Stefano
  • Patiño-García, Ana
  • Alfranca, Arantzazu
  • Garcia-Castro, Javier
Osteosarcoma (OS) is a highly aggressive tumor characterized by malignant cells producing pathologic bone; the disease presents a natural tendency to metastasize. Genetic studies indicate that the OS genome is extremely complex, presenting signs of macro-evolution, and linear and branched patterns of clonal development. However, those studies were based on the phylogenetic reconstruction of next-generation sequencing (NGS) data, which present important limitations. Thus, testing clonal evolution in experimental models could be useful for validating this hypothesis. In the present study, lentiviral LeGO-vectors were employed to generate colorimetric red, green, blue (RGB)-marking in murine, canine, and human OS. With this strategy, we studied tumor heterogeneity and the clonal dynamics occurring in vivo in immunodeficient NOD.Cg-Prkdcscid-Il2rgtm1Wjl/SzJ (NSG) mice. Based on colorimetric label, tumor clonal composition was analyzed by confocal microscopy, flow cytometry, and different types of supervised and unsupervised clonal analyses. With this approach, we observed a consistent reduction in the clonal composition of RGB-marked tumors and identified evident clonal selection at the first passage in immunodeficient mice. Furthermore, we also demonstrated that OS could follow a neutral model of growth, where the disease is defined by the coexistence of different tumor sub-clones. Our study demonstrates the importance of rigorous testing of the selective forces in commonly used experimental models.
Repisalud
Publication Artículo científico (JournalArticle)

c-Fos induces chondrogenic tumor formation in immortalized human mesenchymal progenitor cells

  • Abarrategi, Ander
  • Gambera, Stefano
  • Alfranca, Arantzazu
  • Rodriguez-Milla, Miguel A
  • Perez-Tavarez, Raquel
  • Rouault-Pierre, Kevin
  • Waclawiczek, Alexander
  • Chakravarty, Probir
  • Mulero, Francisca
  • Trigueros, César
  • Navarro, Samuel
  • Bonnet, Dominique
  • Garcia-Castro, Javier
Mesenchymal progenitor cells (MPCs) have been hypothesized as cells of origin for sarcomas, and c-Fos transcription factor has been showed to act as an oncogene in bone tumors. In this study, we show c-Fos is present in most sarcomas with chondral phenotype, while multiple other genes are related to c-Fos expression pattern. To further define the role of c-Fos in sarcomagenesis, we expressed it in primary human MPCs (hMPCs), immortalized hMPCs and transformed murine MPCs (mMPCs). In immortalized hMPCs, c-Fos expression generated morphological changes, reduced mobility capacity and impaired adipogenic- and osteogenic-differentiation potentials. Remarkably, immortalized hMPCs or mMPCs expressing c-Fos generated tumors harboring a chondrogenic phenotype and morphology. Thus, here we show that c-Fos protein has a key role in sarcomas and that c-Fos expression in immortalized MPCs yields cell transformation and chondrogenic tumor formation.
Repisalud
Publication Artículo científico (JournalArticle)

Clinical and epidemiological changes in severe viral respiratory infections in pediatric patients after the COVID-19 pandemic in Spain.

  • García-García, María Luz
  • Alonso-López, Patricia
  • Alcolea, Sonia
  • Arroyas, María
  • Iglesias-Caballero, Maria
  • Sánchez-León, Rocío
  • Hurtado-Gallego, Jara
  • Mas-Lloret, Vicente
  • Pozo Sanchez, Francisco
  • Casas Flecha, Inmaculada
  • Calvo, Cristina
The COVID-19 pandemic and associated public health measures disrupted the circulation of respiratory viruses worldwide. However, the long-term impact of these changes on pediatric respiratory tract infections (ARTIs) remains incompletely understood. We conducted a prospective study in children under 14 years hospitalized for ARTIs in Severo Ochoa Hospital (Spain) from January/2006 to September/2023. The cohort was divided into three periods: pre-pandemic (T1), pandemic (T2), and post-pandemic (T3). Clinical and virological results were compared. 6048 children were included (T1:5,101; T2:122; T3:825). Viral detection increased in T3 (91%) compared to T1 (78.7%) and T2 (69.5%), p < 0.001, with higher rate of coinfections, p < 0.001, and pneumonia diagnoses, p < 0.001. HRV and RSV were the most frequent viruses across periods, with HRV maintaining year-round circulation and RSV showing marked seasonal disruption in T2, followed by return to its typical winter pattern in T3. Detection of PIV and HMPV increased in T3, with altered seasonal peaks and a shift toward older age groups. Influenza infections, nearly absent in T2, re-emerged in T3 with delayed seasonal peaks and higher median ages. HBoV circulation declined and became more evenly distributed throughout the year. Clinically, children in T3 were older, with more hypoxia, radiological infiltrates, and pneumonia, while bronchiolitis cases decreased. Most pneumonia cases in T3 had a viral etiology, with HRV, RSV, HMPV, and PIV as the main contributors. Post-pandemic shifts in viral circulation and disease profiles among children with ARTIs highlight the ongoing impact of COVID-19 on pediatric respiratory health. The increased burden of viral pneumonia and the change in seasonal distribution of infections underscore the need for updated surveillance, diagnostic strategies, and prevention programs tailored to the post-pandemic context.
Repisalud
Publication Artículo científico (JournalArticle)

Impact of Nirsevimab on RSV and Non-RSV Severe Respiratory Infections in Hospitalized Infants.

  • García-García, María Luz
  • Alonso-López, Patricia
  • Alcolea, Sonia
  • Arroyas, M
  • Pozo Sanchez, Francisco
  • Casas Flecha, Inmaculada
  • Iglesias-Caballero, Maria
  • Sánchez-León, Rocío
  • Hurtado-Gallego, Jara
  • Calvo, Cristina
Background: Nirsevimab, a monoclonal antibody providing passive immunity against RSV infections in infants, was introduced in Spain in October 2023 for children under 6 months and those born during the epidemic season. This study aimed to compare the clinical and virological characteristics of respiratory infections in hospitalized infants before and after nirsevimab introduction. Methods: We carried out a prospective study across two hospitals in Madrid during the 2022-2023 and 2023-2024 epidemic seasons. The study included infants under 12 months of age that were hospitalized with lower respiratory tract infections (LRTIs). Clinical, epidemiological, and virological data were analyzed and compared between the periods before and after the introduction of nirsevimab, as well as according to whether the infants had received this preventive treatment. Results: A total of 669 infants were included: 480 from October 2022 to March 2023 (S1) and 189 from October 2023 to March 2024 (S2). Respiratory infection-related admissions decreased by 62.5% in S2, with a 74.5% reduction in ICU admissions. RSV-related admissions decreased by 78%, HMPV by 36.6%, and adenovirus by 69.5%. Infants in S2 were older (p = 0.001) and had shorter hospital stays (p < 0.001) than in S1. Of 63 (33%) infants in S2 who received nirsevimab, 11 (17%) were diagnosed with RSV. High-flow oxygen use was less frequent among RSV patients treated with nirsevimab (p = 0.002). Conclusions: Nirsevimab introduction was significantly associated with reduced hospitalizations and severity of RSV and other respiratory infections. Its use was associated with fewer admissions and reduced need for intensive care, especially in RSV-infected infants but also in HMPV and adenovirus-infected infants.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Bone microenvironment signals in osteosarcoma development

  • Alfranca, Arantzazu
  • Martínez-Cruzado, Lucía
  • Tornin, Juan
  • Abarrategi, Ander
  • Amaral, Ana Teresa
  • Álava, Enrique de
  • Menéndez, Pablo
  • García-Castro, Javier
  • Rodríguez, René
The bone is a complex connective tissue composed of many different cell types such as osteoblasts, osteoclasts, chondrocytes, mesenchymal stem/progenitor cells, hematopoietic cells and endothelial cells, among others. The interaction between them is finely balanced through the processes of bone formation and bone remodeling, which regulates the production and biological activity of many soluble factors and extracellular matrix components needed to maintain the bone homeostasis in terms of cell proliferation, differentiation and apoptosis. Osteosarcoma (OS) emerges in this complex environment as a result of poorly defined oncogenic events arising in osteogenic lineage precursors. Increasing evidence supports that similar to normal development, the bone microenvironment (BME) underlies OS initiation and progression. Here, we recapitulate the physiological processes that regulate bone homeostasis and review the current knowledge about how OS cells and BME communicate and interact, describing how these interactions affect OS cell growth, metastasis, cancer stem cell fate and therapy outcome., This work was supported by the Plan Nacional de I+D+i 2008–2011 [ISCIII/FEDER (PI11/00377, Miguel Servet Program CP11/00024 & CP11/00206) and RTICC (RD12/0036/0015, RD12/0036/0027 & RD12/0036/0017)], the Plan Nacional de I+D+i 2013–2016 [MINECO/FEDER (SAF-2013-42946-R & SAF2013-43065)], Grupo Español de Investigación en Sarcomas (GEIS), Generalitat de Catalunya (Grupo SGR330), Health Canada and Obra Social La Caixa/Fundaciò Josep Carreras., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature

  • Rodríguez-Otero, P.
  • Mateos, M.V.
  • Martínez-López, J.
  • Hernández, M.T.
  • Ocio, E.M.
  • Rosiñol, L.
  • Martínez, R.
  • Teruel, A.I.
  • Gutiérrez, N.C.
  • Bargay, J.
  • Bengoechea, E.
  • González, Y.
  • de Oteyza, J.P.
  • Gironella, M.
  • Nuñez-Córdoba, J.M.
  • Encinas, C.
  • Martín, J.
  • Cabrera, C.
  • Palomera, L.
  • de Arriba, F.
  • Cedena, M.T.
  • Puig, N.
  • Oriol, A.
  • Paiva, B.
  • Bladé, J.
  • Lahuerta, J.J.
  • San Miguel, J.F.
Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18.6% remained alive and progression free after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60.8% as compared with 11.8% for those progressing within the first 5 years. Hemoglobin (Hb) = 12 g/dl (OR 2.74, p = 0.001) and MGUS-like profile (OR 4.18, p = 0.005) were the two baseline variables associated with long-term disease-free survival. Upon including depth of response (and MRD), Hb = 12 g/dl (OR 2.27) and MGUS-like signature (OR 7.48) retained their predictive value along with MRD negativity (OR 5.18). This study shows that despite the use of novel agents, the probability of disease control at 5 years is still restricted to a small fraction (18.6%) of elderly MM patients. Since this endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-treatment biomarkers helpful in predicting the likelihood of disease control at 5 years.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Caveats and pitfalls of SOX1 autoantibody testing with a commercial line blot assay in paraneoplastic neurological investigations

  • Ruiz-García, Raquel
  • Martínez Hernández, Eugenia
  • García-Ormaechea, Milagros
  • Español-Rego, Marta|||0000-0001-5497-2276
  • Sabater, Lidia
  • Querol, Luis|||0000-0002-4289-8264
  • Illa, Isabel|||0000-0002-2186-2684
  • Dalmau, Josep|||0000-0001-5856-2813
  • Graus Ribas, Francesc|||0000-0002-8924-8322
SOX1 autoantibodies are considered markers of small cell lung cancer (SCLC) and paraneoplastic neurological syndromes (PNS) and are usually determined by commercial line blot in many clinical services. Recent studies suggested that SOX1 autoantibodies also occur in patients with neuropathies unrelated to SCLC, questioning the value of SOX1 autoantibodies as paraneoplastic biomarkers. Here, we compared the specificity and sensitivity of a commercial line blot (Euroimmun, Lübeck, Germany) with those of an in house cell-based assay (CBA) with HEK293 cells transfected with SOX1. Overall, 210 patients were included in the study, 139 patients with polyneuropathies without SCLC, and 71 with disorders associated with SOX1 autoantibodies detected with the in-house CBA. Forty one of these 71 cases had been referred to our laboratory for onconeuronal antibody assessment and 30/71 were patients with known PNS and SCLC. None of the patients with polyneuropathies had SOX1 autoantibodies by either line blot or CBA (specificity of the immunoblot: 100%; 95%C.I.: 97.8-100). Among the 71 patients with CBA SOX1 autoantibodies, only 53 were positive by line blot (sensitivity: 74.6%; 95%C.I.: 62.9-84.2). Lung cancer was detected in 37/41 (90%; 34 with SCLC) patients referred for onconeuronal antibody assessment and 34 of them also had a PNS. Our study confirms the association of SOX1 autoantibodies with SCLC and PNS. The line blot test misses 25% of the cases; therefore, to minimize the frequency of false negative results we recommend the use of a confirmatory test, such as CBA, in patients suspected to have a SCLC-related PNS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease

  • Gaig, Carles|||0000-0002-7113-8125
  • Ercilla, Guadalupe
  • Daura i Ribera, Xavier|||0000-0001-9235-6730
  • Ezquerra, Mario|||0000-0003-3246-6641
  • Fernández-Santiago, Rubén|||0000-0002-4582-0702
  • Palou, Eduard|||0000-0003-1544-1485
  • Sabater, Lidia
  • Höftberger, Romana|||0000-0002-5769-1100
  • Heidbreder, Anna
  • Högl, Birgit
  • Iranzo, Alex|||0000-0002-5618-8271
  • Santamaria Cano, Joan|||0000-0003-0879-4135
  • Dalmau, Josep|||0000-0001-5856-2813
  • Graus Ribas, Francesc|||0000-0002-8924-8322
We investigated the associations with HLA and microtubule-associated protein tau (MAPT) H1 haplotype in anti-IgLON5 disease, a recently identified disorder characterized by gait instability, brainstem dysfunction, and a prominent sleep disorder in association with IgLON5 antibodies and pathologic findings of a novel neuronal-specific tauopathy. We compared the HLA alleles and MAPT H1/H1 genotype of 35 patients with anti-IgLON5 with healthy controls. The on-line server tool NetMHCIIpan 3.1 was used to predict the IgLON5 peptide binding to HLA Class II molecules. The HLA-DRB1*10:01-DQB1*05:01 haplotype was overrepresented in patients with anti-IgLON5 disease (OR = 54.5; 95% CI: 22.2-133.9, p < 0.0001). In addition, HLA-DQA was genotyped in 27 patients, and 25 (92.6%) of them had DQ molecules composed by DQA1*01 and DQB1*05 chains compared with 148/542 (27.3%) controls (OR = 43.9; 95% CI: 10.4-185.5, p < 0.0001). Patients DRB1*10:01 positive developed more frequently sleep or bulbar symptoms than those carrying other HLA alleles (70.0% vs 26.7%; p = 0.011). Prediction algorithms identified 2 IgLON5 peptides (1 located in the signal sequence) that showed strong binding to HLA-DRB1*10:01 and other HLA-DRB1, but not to HLA-DQA and HLA-DQB molecules. The MAPT H1/H1 homozygous genotype was present in 20/24 (83.3%) anti-IgLON5 Caucasian patients compared with 54/116 (46.5%) healthy controls (p = 0.0007). The robust association of anti-IgLON5 disease with distinct HLA Class II molecules supports a primary autoimmune origin. The significant association of MAPT H1 haplotype also suggests that an underlying neurodegenerative process could be involved in anti-IgLON5 disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma, impact of an MGUS-like signature

  • Rodriguez-Otero, Paula|||0000-0001-5236-7785
  • Mateos, M. V.|||0000-0003-2390-1218
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Hernández, Miguel Teodoro|||0000-0002-6576-7881
  • Ocio, Enrique M.|||0000-0002-5765-0085
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Martínez Martínez, Rafael
  • Teruel, Ana Isabel|||0000-0003-1559-7607
  • Gutierrez, Norma|||0000-0001-5834-9510
  • Bargay, Joan|||0000-0002-6739-3916
  • Bengoechea, Enrique
  • González, Yolanda
  • Perez de Oteyza, Jaime|||0000-0002-8338-2037
  • Gironella, Mercedes|||0000-0002-8106-8909
  • Nuñez-Córdoba, Jorge
  • Encinas, Cristina|||0000-0002-9001-9754
  • Martín Sánchez, Jesús|||0000-0003-4250-4824
  • Cabrera-Lopez, Carlos|||0000-0002-6251-4854
  • Palomera, Luis|||0000-0003-0359-7191
  • De Arriba, Felipe|||0000-0002-4451-1318
  • Cedena, María Teresa|||0000-0001-5851-3720
  • Puig, Noemí|||0000-0001-7535-3861
  • Oriol, Albert|||0000-0001-6804-2221
  • Paiva, Bruno|||0000-0003-1977-3815
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • Lahuerta, J. J.|||0000-0002-3393-9570
  • San Miguel, Jesús F.
Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18.6% remained alive and progression free after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60.8% as compared with 11.8% for those progressing within the first 5 years. Hemoglobin (Hb) ≥ 12 g/dl (OR 2.74, p = 0.001) and MGUS-like profile (OR 4.18, p = 0.005) were the two baseline variables associated with long-term disease-free survival. Upon including depth of response (and MRD), Hb ≥ 12 g/dl (OR 2.27) and MGUS-like signature (OR 7.48) retained their predictive value along with MRD negativity (OR 5.18). This study shows that despite the use of novel agents, the probability of disease control at 5 years is still restricted to a small fraction (18.6%) of elderly MM patients. Since this endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-treatment biomarkers helpful in predicting the likelihood of disease control at 5 years.
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

Location of Latent Forensic Traces Using Multispectral Bands

  • Miralles Mosquera, Samuel
  • Alarcos Alcázar, Bernardo|||0000-0002-4455-5716
  • Gardel Vicente, Alfredo|||0000-0001-7887-4689
In this paper, a conventional camera modified to capture multispectral images, has been used to locate latent forensic traces with a smart combination of wavelength filters, capturing angle, and illumination sources. There are commercial multispectral capture devices adapted to the specific tasks of the police, but due to their high cost and operation not well adapted to the field work in a crime scene, they are not currently used by forensic units. In our work, we have used a digital SLR camera modified to obtain a nominal sensitivity beyond the visible spectrum. The goal is to obtain forensic evidences from a crime scene using the multispectral camera by an expert in the field knowing which wavelength filters and correct illumination sources should be used, making visible latent evidences hidden from the human-eye. In this paper, we show a procedure to retrieve from latent forensic traces, showing the validity of the system in different real cases (blood stains, hidden/erased tattoos, unlocking patterns on mobile devices). This work opens the possibility of applying ultispectral inspections in the forensic field specially for operational units for the location of latent through non-invasive optical procedures., Instituto Universitario de Investigación en Ciencias Policiales